Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults

• Asıl Yazarlar: Patrick Yassini (Yazar), Mark Hutchens (Yazar), Yamuna D. Paila (Yazar), Lorraine Schoch (Yazar), Anne Aunins (Yazar), Uma Siangphoe (Yazar), Robert Paris (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Taylor & Francis Group, 2023-01-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

This interim analysis of an ongoing phase 1 randomized clinical trial evaluated the safety, reactogenicity, and immunogenicity of mRNA-1283, a next-generation SARS-CoV-2 messenger RNA (mRNA)-based vaccine encoding two segments of the spike protein (i.e. receptor binding and N-terminal domains). Heal...